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1.  ABSTRACT  
 
Introduction: Psoriasis is a systemic disease that mainly affects the skin. It is a 
common disease, with at least 100 million individuals affected worldwide and with higher 
prevalence rates in countries at higher latitudes. Although its etiology is not fully 
understood, it is considered a multifactorial disease, with great contribution of genetic 
factors and also epigenetic and environmental factors. Among the latter ones, ultraviolet 
radiation (UVR) is of special interest, as its effects are exploited in the treatment of this 
disease. The amount of UVR exposure could be influencing the typical geographical 
distribution of psoriasis.  
 
Objective: This paper aims to find a correlation between the prevalence of psoriasis 
and UVR exposure. 
 
Materials and methods: International estimates of ambient exposure to UVR, derived 
from satellite measurements, and prevalence data from epidemiology surveys were used 
to develop a correlation analysis, using Pearson’s correlation factor. 
 
Results: A negative Pearson’s correlation factor of -0.55 (p<.05) was obtained, with 
a linear R2 of 0.304.  
 
Conclusions: Our findings suggest that populations of countries with higher UVR 
exposure, present a lower prevalence of this disease. The effect size for psoriasis’ 
prevalence indicates that UVR may account for a considerable portion (30%) of the 
variability in psoriasis’ prevalence.  
 
Keywords: psoriasis, prevalence, ultraviolet radiation, epidemiology, climate. 
  
The present work expresses the opinion of the author and not that of the Faculty of 
Medicine of the University of Lisbon.  
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1.   RESUMO 
 
Introdução: A psoríase é uma doença sistémica que afeta primordialmente a pele. É 
uma doença comum, afetando mais de 100 milhões de indivíduos por todo o mundo, que 
apresenta uma prevalência superior em países com maior latitude. Apesar da sua etiologia 
não se encontrar totalmente esclarecida, é considerada uma doença multifatorial, com 
grande contribuição de fatores genéticos, mas também de fatores epigenéticos e 
ambientais.  Entre estes últimos, a radiação ultravioleta apresenta particular interesse, 
uma vez que se trata de um fator climático que é também usado na abordagem terapêutica 
desta doença, podendo contribuir para a distribuição geográfica característica da psoríase.  
 
Objetivo: O objetivo deste trabalho é verificar se existe uma correlação entre a 
prevalência da psoríase e a exposição a radiação ultravioleta. 
 
Materiais e métodos: Estimativas internacionais dos níveis de exposição ambiental de 
radiação ultravioleta, obtidos por medições via satélite, e dados de prevalência 
provenientes de estudos epidemiológicos, são confrontados num estudo de correlação 
estatística, utilizando o coeficiente de correlação de Pearson. 
 
Resultados: Foi obtida uma correlação negativa de -0.55 (p<.05), com um valor de R2 
de 0.304. 
 
Conclusão: Os resultados obtidos sugerem que países com valores de exposição a 
radiação ultravioleta superiores apresentam valores de prevalência de psoríase inferiores, 
com um ‘effect size’ que indica que a variação deste fator climático, pode ser responsável 
por 30% da variação da prevalência.   
 
Palavras-chave: psoríase, prevalência, radiação ultravioleta, epidemiologia, clima 
O presente trabalho exprime a opinião do autor e não da Faculdade de Medicina da 
Universidade de Lisboa. 
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3.   INTRODUCTION 
 
Psoriasis is a chronic, immune-mediated, systemic disease that mainly affects the skin 
and the joints1 and recent estimates suggest that at least 100 million individuals are 
affected worldwide.2  
Although some controversy exists regarding the mild and moderate forms, severe 
psoriasis is associated with cardiovascular comorbidity.3,4 Cardiovascular diseases are the 
leading cause of death among these patients with a sevenfold increased risk of myocardial 
infarction.5 Furthermore it is associated to a great psychologic burden, with lower quality 
of life and greater work impairment.6  
Following a report from 2010, that estimated psoriasis to account for 1 050 660 years 
of healthy life lost globally, twice as many years as for acute hepatitis C, the WHO 
recognized the urgent need to raise awareness and to fight stigmatization suffered by 
psoriatic patients leading to the release of a global report on psoriasis, in 2016.7  
 
Pathophysiology 
Psoriasis pathology involves a cross-talk between innate and adaptive immunity, 
involving keratinocytes, dendritic cells (DCs) and T-cells.8 
The abnormalities observed range from antigen presentation, differentiation of T 
helper cell populations and enhanced IL-17 response.9 
-­‐   Innate immune system  
External insults to a healthy skin result in the release of self-nucleotides from the skin, 
that form complexes with the epidermis-produced antimicrobial peptide IL-37 
(cathelicidin - cAMP). These complexes are recognized by toll-like receptor (TLR) on 
the surface of plasmacytoid dendritic cells (pDCs) and are subsequently intracellularly 
degraded. If the cAMP binds to a foreign DNA, an interferon (IFN)-driven response is 
triggered. In the case of psoriatic skin, adding to the fact that production of cAMP is 
exacerbated, the IFN-driven response is also triggered following the formation of host-
   7  
DNA/cAMP complexes. These two factors result in a pathologic cascade of activation of 
myeloid dendritic cells, via the release of IFN-alfa and TNF-alfa. 
-­‐   IL 12/23 axis 
The activated myeloid DCs produce TNF-alfa, IL12 and IL23, which stimulate Th1, 
Th22 and Th17. Th17 plays a central role in psoriasis, by producing IL-17 that acts on 
keratinocytes, and induces them to proliferate and produce TNF and CCL20 (a 
chemotactic for T-cells and DCs). This results in the recruitment of additional 
inflammatory cells to the skin. 
-­‐   Antigen presentation 
CD8+ T-cells also play a role, and are activated by pDCs presenting antigens, both in 
the lymph nodes (naïve T-cells) and in the dermis (memory resident T cells). 
Subsequently, in the epidermis, the activated CD8+ T-cells encounter the Major 
histocompatibility complex class I (MHC-I) on the surface of keratinocytes and trigger 
the local release of soluble factors – cytokines, chemokines and innate immune mediators. 
 
Etiology  
The etiology of psoriasis is complex and not completely understood, but there is clear 
evidence of an important genetic component, with concordance rates of 70% and 20%, 
for monozygotic and dizygotic twins, respectively.9 Furthermore, more than 40 
susceptibility loci associated, mostly regarding genes that code proteins with immune 
functions are involved in the pathophysiologic processes described above.,10  
In addition to the existence of this genetic predisposition, documented investigations 
regarding phenomena of DNA methylation, histone modification and non-coding RNA; 
as well as evidence of association to among others, UV radiation, medication, alcohol 
intake, smoking, diet and obesity, infection and mental stress have led to the belief that 
the interplay between genetic, epigenetic and environmental factors determines the 
development of this disease 11 
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Epidemiology 
Reviews on the global epidemiology of psoriasis have revealed an apparent upward 
trend in the prevalence of this disease, but they have also systematically shown a 
significant variation of its occurrence according to the geographic region, with higher 
prevalence rates reported in countries at higher latitudes – “equator effect”.12 This effect 
is not yet understood, and part of this variation might be attributed to the different 
methodologies used in the available studies concerning the epidemiology of psoriasis, 
such as definition of prevalence, case definition of psoriasis, different population ages 
and sampling techniques.  Nevertheless,  genetic and epigenetic factors, historic 
migration patterns, as well as climate factors may contribute to this geographic 
variation.13  
 
Climate and psoriasis  
Regarding the influence of climate on psoriasis, a global investigation that sought to 
correlate latitude with psoriasis’ prevalence, was conducted, by Jacobson et al., but only 
demonstrated a non-significant correlation between the two.14 Although the statistical 
analysis of this latter study had been contested (and later defended by its author), no 
further investigations at a global scale were performed.15,16   
In another recent study, concerning the population of the United Kingdom, a 
significant correlation between latitude and prevalence was found.17  
It has also been suggested that, as in other diseases, climatic confounders and not 
latitude itself, may account for these geographic variations.13 One factor of particular 
interest is UV radiation, a climate factor that depends, among others, on latitude. It is 
important to look closely at the relationships between these different factors when 
studying their correlation with psoriasis. 
 
UV radiation effects  
Ultraviolet radiation is part of the spectrum of electromagnetic radiation emitted by 
the sun. According to its biologic effects, it can be divided into UVA (wavelength 400-
320 nm), UVB (320-290 nm) and UVC (290-200 nm).18 
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Since 100% of UVC and 90% of UVB are absorbed by atmospheric ozone, UVA and 
UVB are the solar ultraviolet radiation of importance to human health.18  







UVR is responsible for different effects on the skin (Table 1). Sun exposure 
demonstrates a U-shaped exposure-disease association, with minimal exposure doses 
being required for induction of synthesis of vitamin D, which is essential for locomotor 
system health; and high exposure being associated to skin cancer.20  
Regarding the immunosuppressive effects of UVR, which have been extensively 
studied since their first description in the late 1970s, a relatively new discipline of 
biomedical research, namely photoimmunology, has been developed. 21 Although the field 
first emerged due to the clinical observation of UVR-induced skin cancer, its further 
growth has also facilitated the development of standardized, efficient, phototherapies for 
disorders, such as psoriasis, atopic dermatitis and T-cell skin lymphoma.22–24  
Furthermore, a beneficial effect of UVR on the prevalence of some autoimmune 
disorders, such as type 1 diabetes and multiple sclerosis has been proposed. These effects 
can be attributed to UVR-induced immunomodulatory mechanisms explained below.25  
Immunosuppression by UV radiation involves multiple pathways, Langerhans cells 
and regulatory T-cells being its main orchestrators.26 Both UVA and UVB contribute to 
immunosuppression and it is believed that they have synergetic effects, given the fact that 
sunlight is more suppressive than either one of them alone.27 Here we summarize some 
in table 2.  
Acute effects 
•   Sunburn; 
•   Tanning; 
•   Epidermal thickening; 
•   Vitamin D production; 
•   Immunologic effects. 
Chronic effects 
•   Carcinogenesis; 
•   Immunosuppresion. 
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Table  2  Immunosuppressive  effects  of  ultraviolet  radiation  on  skin  
Isomerization of 
urocanic acid (trans 
to cis) 28 
-­‐   Stimulation of the production of IL-10 
DNA damage21 -­‐   Damage to Langerhans cells and keratinocytes; 
-­‐   Switch in the production of molecules by the immune 
system, to molecules with anti-inflammatory effects; 
Regulatory T cells21 -­‐   Diminished generation of effector T cells; 
-­‐   Increased number of regulatory T cells;  
Antigen presenting 
cells (APC)28 
-­‐   Migration and, if the exposure-dose is high enough, 
apoptosis of Langerhans cells; 
-­‐   Depletion of the major antigen presenting cells (APCs) 
in the skin; 
-­‐   Impaired ability to present antigens; 
Cytokines28 -­‐   Keratinocytes stimulated by UV produce different 
mediators (IL-10, TNF-alfa, PGE2, serotonin, PAF, 
CGRP, alfa-MSH). 
 
Considering that the above summarized immunologic effects of UVR antagonize the 
ones that underlie psoriasis’ pathophysiology, other than explaining the efficacy of UV 
based treatments for psoriasis, it is reasonable to hypothesize the existence of an 
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4.   RELEVANCE OF THE STUDIED SUBJECT 
 
Knowledge concerning the epidemiology and etiology of diseases is of undeniable 
importance to allow its adequate management. Even though psoriasis has been gaining 
more attention in recent years, it is still a disease with knowledge gaps. 
In light of the most recent findings, it is obvious that genetics play a central role in 
psoriasis’ etiology, but more research is needed to conclude whether other factors also 
are involved. 
The aim of this study is to investigate a potential association between UV radiation 
and the prevalence of psoriasis in different countries. 
Although a negative correlation between the two variables would not prove causality, 
it would be an important step towards this direction. In that case this study can bring us 
closer to determining the role of UVR in psoriasis pathogenesis, either as an independent 
necessary factor or as a factor influencing only populations that share a common genetic 
pool.  
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5.   MATERIALS AND METHODS 
 
This study used only previously published data. Estimates of international ambient 
erythemally weighted UVR, derived from satellite measurements and prevalence data 
from epidemiology surveys were used to develop a correlation analysis. 
Literature research and inclusion and exclusion criteria 
Articles were identified using the PubMed database and by following reference lists. 
The search was performed using the keywords "Psoriasis/epidemiology"[Mesh] AND 
"Prevalence"[Mesh] NOT "Arthritis, Psoriatic"[Mesh] (385 articles). Given the paucity 
of data, no restrictions regarding date of studies were applied. 
Titles and abstracts were reviewed for exclusion criteria, which were: 
•   Non-English full-text available; 
•   Studies concerning only psoriatic arthritis; 
•   Correlation studies with no epidemiologic data regarding psoriasis’ 
prevalence; 
•   Only self-reported based prevalence studies; 
•   Prevalence studies in sub-populations not likely to be representative of the 
general population or of non-country regions.  
To assess the quality of the studies, only studies with data reporting methods 
differentiating diagnostic method, age of the subjects, year of study and sample size were 
considered.  
 
Data extraction  
From each included article, the following data was extracted: prevalence estimate age-
related (all ages, adults and children), diagnostic method, year of study and sample size. 
From the selected articles, data was combined to eliminate duplicates.  
When more than one prevalence estimate value was available for a specific 
geographic region, the most recent one was chosen. 
Prevalence data in population of all ages was obtained from 17 different countries, 
for adults from 7 different countries and for children from 5 different countries.  
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UV radiation exposure 
The data concerning the UV radiation was obtained through the WHO database, in 
the category “Public health and environment”, in the “Ultraviolet radiation” folder, under 
the topic “Exposure to solar ultraviolet radiation – data by country”. The data (table 3) 
was originally collected by WHO in order to evaluate the burden of disease resulting from 
exposure to ultraviolet radiation.  
The estimates are population-weighted average daily ambient UVR level, calculated 
from satellite data, and the used unit is J/m2. It concerns the period between 1997-2003 
for selected countries.29 
Statistical analyses 
Statistical analyses of the relationship between the prevalence and climate data were 
performed using SPSS to compute the Pearson’s correlation factor. 
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Table  3  Exposure  to  solar  ultraviolet  radiation  -­‐  data  by  country.29    
Abbreviations:  UV,  ultraviolet.  















Republic of Korea 2535 




United Republic of Tanzania 5483 
United Kingdom 1576 
United States of America 2736 
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Table  4  Prevalence  of  psoriasis  in  population  of  all  ages.    
PD,  physician  diagnose;  DD,  dermatologist  diagnose;  SR,  self-­‐reported.  
Country Prevalence of 
psoriasis in 
population of all 
ages (%) 
Sample size Diagnostic 
method 
Brazil 1.3130 8947 PD 
China 0.4731,32 17 345 SR and PD 
Denmark  2.2033 nationwide PD and DD 
Egypt 0.1932,34 8 008 DD 
Germany 2.5332,35 1 344 071 PD and DD 
Israel 2.6936 4 400 000 DD 
Japan 0.4437 128 000 000 PD and DD 
Norway 1.4032,38 2 508 DD 
Poland 1.4532,39 2 161 832 PD and DD 
Republic of Korea 0.6240 51 574 044 
 
PD 
Sri Lanka 0.4432,41 1 806 PD 
Sweden 1.9532,42 - PD and DD 
Tunisia 0.5732,43 5 778 DD 
Turkey 0.4244 18 771 SR and PD 
United Republic of 
Tanzania 
0.0932,45 1 114 PD and DD 
United Kingdom 1.8732,46 7 520 293 PD 
United States of 
America 
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Table  5  Prevalence  of  psoriasis  in  population  of  adults.    
PD,  physician  diagnose;  DD,  dermatologist  diagnose.  
  
Table  6  Prevalence  of  psoriasis  in  population  of  children.    
PD,  physician  diagnose;  DD,  dermatologist  diagnose  
  




Sample size Diagnostic 
method 
Australia 6.6032,48 1 457 PD and DD 
Canada 2.5449 10 774 802 PD 
Croatia 1.2132,50 6 711 DD 
Germany 2.0332,51 90 880 PD and DD 
Norway 8.0052 2 508 DD 
United Kingdom 1.3032,53 58 257 PD 
United States of 
America 
2.2032,47 nationwide PD and/or DD 




Sample size Diagnostic 
method 
Egypt 0.0632,54 6162 DD 
Germany 0.4532,55 293 181 PD and DD 
Italy 0.2032,56 145 233 PD 
Netherlands 0.1757 - PD and DD 
United States of 
America 
0.1358 4 300 000 PD and DD 
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6.   RESULTS  
 
 
Prevalence of psoriasis in population of all ages 
Estimates of psoriasis’ prevalence were obtained from 17 different countries. 
The prevalence of psoriasis in studies with participants of all ages ranged from 0.09% 
(Republic of Tanzania)45 and 2.69% (Israel)36 (Table 4). 
In Europe, estimate prevalence rates varied between 1.40% (Norway)38 and 2.53% 
(Germany)35. In Asia, rates ranged between 0.42% (Turkey)44 and 2.69% (Israel)36. 
Estimates in Africa ranged between 0.09% in the Republic of Tanzania45 and 0.57% in 
Tunisia43. For the continents of North and South America only two countries were 
included: 1.43% (USA)47 and 1.31% (Brazil)30. 
No studies from Oceania were identified. 
 
Prevalence of psoriasis in population of adults 
Data from 7 different countries was obtained. In Europe, prevalence ranged between 
1.21% (Croatia)50 and 8% (Norway)52. Data from Australia revealed a prevalence of 
6.6%48. In North America, prevalence ranged from 2.20% (USA)47 to 2.54% (Canada)49. 
No data from South America, Asia or Africa was found. (Table 5) 
 
Prevalence of psoriasis in population of children 
Data was identified from 5 countries only, ranging from 0.06% (Egypt)54 to 0.45% 
(Germany)55. (Table 6).  
 
Relationship between UVR and prevalence rates 
We examined this relationship, using Pearson’s correlation factor and linear 
regression. The data regarding adult and children populations is too scarce and did not 
allow us to perform a linear regression analysis. 
As for the populations of all ages, a negative correlation factor of -0.55 was obtained, 
with a linear R2 of 0.304. 
 
  










Figure  1  Relationship  between  ultraviolet  radiation  and  prevalence  of  psoriasis  in  population  of  all  ages.  
Abbreviations:  UVR,  ultraviolet  radiation  
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7.   DISCUSSION    
In this analysis, a Pearson correlation was conducted to examine the relationship 
between the median UVR exposure of countries and the respective prevalence of psoriasis 
in populations of all ages. Prevalence of psoriasis was negatively related to UVR, r (17)= 
-.55, p<.05. These findings suggest that populations of countries with higher UVR 
exposure, present a lower prevalence of this disease. The effect size for psoriasis 
prevalence (r2 =.30) suggests that UVR accounts for a considerable portion (30%) of the 
variability in psoriasis’ prevalence. Although not statistically considered an outlier, a 
point that is out-of-rule is visible in the scatterplot graphic, namely Israel. Excluding this 
value, the correlation results in a higher negative value (r (16) = -.70, p < .01).  On the 
other hand, it is important to consider the possibility that this surprisingly high prevalence 
value may be a consequence of the north European origin of a great part of this country’s 
population, demonstrating the importance of genetic factors.   
This is the first study, as able as we were to search in the literature, evaluating the 
relationship between ambient erythemally weighted UVR and the prevalence of psoriasis. 
Two previous studies have sought to establish a correlation between climate factors and 
psoriasis.14,17 These studies focused on latitude, instead of UVR. Although latitude 
provides a rough approximation of the global variation in UVR, due to the elliptical shape 
of the Earth’s orbit, there is a 7% difference in intensity between the hemispheres for any 
level of latitude.59 Also, clearer skies in the southern hemisphere can increase this 
difference up to 10-15%.60 Thus, UVR itself could be a more suitable factor to asses this 
relationship. 
Although the earliest of the two studies, which was made on a global scale, showed 
no statistically significant correlation,14 the most recent one, focusing only on the UK 
population, showed a stronger correlation than the one found in this article.17 This could 
suggest that UVR may influence the prevalence of psoriasis, but only within a population 
from the same genetic pool. 
Studying the scatterplot graphic, it is also possible to identify a cluster in data, formed 
by European countries, where the highest rates in prevalence are observed. This further 
supports the fact that genetics is a more important factor than climate. 
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There are important limitations to this analysis, regarding both data on prevalence and 
radiation. Firstly, the available data lacks standardized definitions for the prevalence 
estimate (point-estimate, period or lifetime estimate) and for the study design adopted by 
each study, which may decrease the liability of this data.  Furthermore, there is a paucity 
of data from certain global regions, such as South America and Oceania. Regarding 
African countries, the existing studies date from the sixties and only describe the 
incidence of the disease and thus meets this study´s exclusion criteria.61–63 This paucity of 
data not only decreases the strength of a global study, but also renders the comparison of 
the influence of UVR among genetically homogenous populations (United Kingdom with 
Canada, Australia or New Zealand) impossible. 
Regarding the UVR data, it is known that its effect on human health depend on the 
amount and type of radiation impinging on the body.60 The amount and type of radiation 
depend on factors such as sun elevation, latitude, altitude, cloud cover, atmospheric ozone 
concentration and ground reflection.59 
In order to study its effects, ambient UVR can be weighted using erythemal response 
function to give biologically effective UVR, expressed as joules per square meter, 
minimal erythemal dose (MED), standard erythemal dose (SED) or the solar UV index.59 
MED depends on skin type and corresponds to the required UVR dose to produce a 
barely perceptible erythema in people with skin type 1 (200 Jm-2); SED is the erythemally 
weighted measure of radiant exposure equivalent to 100 Jm-2 and is independent of skin 
type. Solar UV index is a tool developed to arise public-awareness of the risks of UVR 
and adopt protective measures.60 
Although it is possible to use annual ambient erythemally weighted UVR as a measure 
of a population exposure (as done in this study) its use does not overcome the biases 
created by not considering the true individual UVR exposure experience, which, for most 
subjects, is believed to vary from 5 to 15% of the total ambient UVR.59 On the other hand, 
there is no efficient method to account for the individual differences on behavior and 
clothing among different countries. 
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Another limitation is the fact that different areas of a specific country, have different 
UVR exposure levels. Using the median of the whole country can be a source of biases, 
especially in countries with areas as vast as the USA and China.  
 
In conclusion UVR seems to be significantly negatively correlated to psoriasis 
prevalence in populations of all ages. Nevertheless, there are important limitations. 
Despite the presence of these biases, the results obtained demonstrate that there is 
substrate for further investigation on psoriasis epidemiology. 
In order to expand knowledge in this area, new, standardized methodologic age-
specific studies on global psoriasis prevalence are required in order to allow us to 
understand the causes and patterns of psoriasis, prioritize research needs, investigate the 
natural history of the disease and identify environmental factors influencing psoriasis, 
such as UVR.  
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9.   ANNEXES  
  
Figure  2  Correlation  analyses  between  the  two  variables  UVR  and  prevalence  of  psoriasis  in  population  of  all  ages.  


















 UVR Prevalence 
UVR Pearson Correlation 1 -,552* 
Sig. (2-tailed)  ,022 
N 17 17 
Prevalence Pearson Correlation -,552* 1 
Sig. (2-tailed) ,022  
N 17 17 
*. Correlation is significant at the 0.05 level (2-tailed). 
Descriptive Statistics 
 Mean Std. Deviation N 
UVR 2936,6471 1306,00832 17 
Prevalence 1,2406 ,82814 17 
